women on retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial Retatrutide UK: What Is It

Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, Melander S, Gibson R, Matthews H, Dickson J, Carroll C, Patrick A, Inches J, Silverdale M, Blackledge B, Whiston J, Hu M, Welch J et al (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinsons disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

M+ q}EgqMSz;UNE?R+&m7mYmVT4ae+BL+Ht%! R @]GPP$ him "3T P&4BP$ ^P:!S@h$Mq! !BC(@mhUQIj

Excessive supplementation can cause nausea, vomiting, abdominal cramps, diarrhoea, fishy skin, muscle weakness in people with uremia and seizure disorders in people with seizure disordersand

High quality studies are needed before solid conclusions can be reached about the long-term safety of these supplements